Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Delcath Systems, Inc.
Formation 1988
Purpose specialty pharmaceutical
Headquarters Delaware
Services Pharmaceutical and medical device company focused on oncology
Website http://delcath.com/

Delcath Systems, Inc. Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly-traded specialty pharmaceutical and medical device company that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).


Investment goal date:
Dividends reinvested
Delcath Systems, Inc. DCTH report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-02-08
--
--
Q3 2017
2017-11-09
--
--
Q2 2017
2017-08-08
0.0000
-0.0100
Q1 2017
2017-05-09
0.0000
-0.2500
Q4 2016
2017-03-28
0.0000
-3.6400
Q3 2016
2016-11-11
0.0000
-0.6600
Q2 2016
2016-08-15
0.0000
-4.4800
Q1 2016
2016-05-04
0.0000
-1.2800
Q4 2015
2016-03-18
0.0000
-3.6800
Q3 2015
2015-11-10
0.0000
-1.9200
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks
WATSON DOUGLAS G
1.4500% (136664)
DCTH / DNDN / OSUR / WMGI /
STOLL ROGER G PHD
1.0500% (99145)
CHTP / DCTH /
GRAHAM PETER J
0.1600% (15000)
ATRS / DCTH /
GAGO AGUSTIN V
0.8600% (80944)
DCTH /
HOBBS EAMONN P
1.7100% (162000)
ATRS / DCTH / OSUR /
LEUNG GABRIEL
0.2300% (21485)
AMRI / DCTH /
LADD ROBERT
0.7400% (69534)
DCTH / MGT /
LANGER DENNIS
0.2100% (20000)
DCTH / DRNA / MYGN / MYRX /
MAPES HAROLD
0.1800% (17000)
DCTH /
Contag Pamela Reilly
0.0900% (8507)
DCTH / MBII /
Konidaris Tasos
0.1200% (11678)
DCTH / KDMN / PTX /
Brege Laura
0.1200% (11678)
Koplewicz Harold S
0.4800% (45052)
DCTH /
Rueckert William Dodge
0.4200% (40000)
CHTP / DCTH / MEIP /
Taney Richard
2.2400% (211485)
DCTH /
Philips Laura A
2.1700% (205299)
DCTH /
Taglietti Marco
2.3300% (220000)
DCTH / FRX / NRX / SCYX /
McDonald David
0.5000% (47706)
DCTH /
Keck Barbra
0.2500% (23887)
DCTH /
Kandarpa Krishna
1.6800% (159000)
DCTH /
Purpura John
0.3700% (35398)
DCTH /
Miao Graham G
0.5700% (54000)
DCTH / PDII / PTX /
% ()